Humalog Mix 25 - Instructions For Use, Syringe Pens, Price, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Humalog Mix 25

Humalog Mix 25: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. In case of impaired renal function
11. 11. For violations of liver function
12. 12. Drug interactions
13. 13. Analogs
14. 14. Terms and conditions of storage
15. 15. Terms of dispensing from pharmacies
16. 16. Reviews
17. 17. Price in pharmacies

Latin name: Humalog Mix 25

ATX code: A10AD04

Active ingredient: insulin lispro (insulin lispro)

Producer: Lilly France (France)

Description and photo update: 2018-27-11

Prices in pharmacies: from 1609 rubles.

Buy

Humalog Mix 25 is a hypoglycemic drug for parenteral administration with a rapid onset of action and a medium duration of effect.

Release form and composition

The drug is produced in the form of a suspension for subcutaneous (s / c) administration: a white solution, which, when separated, forms a white precipitate and a supernatant colorless or almost colorless transparent liquid, when shaken, the precipitate is easily resuspended (3 ml in a cartridge: 5 cartridges in a blister, in a cardboard box 1 blister; 1 cartridge built into the QuickPen pen, in a cardboard box 5 syringe pens; each pack also contains instructions for the use of Humalog Mix 25).

1 ml of suspension contains:

• active substance: insulin lispro - 100 IU (international unit);
• auxiliary components: glycerol (glycerin), metacresol, zinc oxide, liquid phenol, sodium hydrogen phosphate, protamine sulfate, 10% hydrochloric acid solution and / or 10% sodium hydroxide solution (pH 7.0-7.8), water for injection.

Pharmacological properties

Pharmacodynamics

Humalog Mix 25 is a hypoglycemic drug that is a DNA (deoxyribonucleic acid) -recombinant analogue of human insulin. It is a combination of fast and medium acting insulin analogs, in which lispro insulin solution is a fast acting analog of human insulin and insulin lispro protamine suspension is a medium acting human insulin analog.

The main action of insulin lispro is to regulate glucose metabolism. In addition, it has anabolic and anti-catabolic effects on various body tissues. It causes an increase in the content of glycogen, glycerol, fatty acids in muscle tissue, an increase in protein synthesis, an increase in the consumption of amino acids. At the same time, it helps to reduce gluconeogenesis, glycogenolysis, ketogenesis, protein catabolism, lipolysis, and the release of amino acids.

Insulin lispro is equimolar to human insulin, but it is characterized by a rapid onset of action with a shorter period of its duration. Compared to normal human insulin, the hypoglycemic effect of Humalog Mix 25 occurs in about 1/4 hour. The rapid onset of action and the early achievement of the peak activity of insulin lispro allows for injections before direct meals (0-1 / 4 hours before meals). The effect of insulin lispro protamine lasts about 15 hours and is similar to that of regular insulin isophane.

Pharmacokinetics

The onset of the effect and the degree of absorption of insulin depend on the site of its administration, the volume (dose) injected and the concentration of insulin in the preparation. It is distributed unevenly in the tissues. Does not cross the placental barrier and does not pass into breast milk.

It is broken down by insulinase to a greater extent in the liver and kidneys. It is excreted through the kidneys - from 30 to 80%.

Indications for use

The use of Humalog Mix 25 is indicated for diabetes mellitus requiring insulin therapy.

Contraindications

• hypoglycemia;
• individual intolerance to the components of Humalog Mix 25.

Humalog Mix 25, instructions for use: method and dosage

Intravenous administration of Humalog Mix 25 is contraindicated!

The suspension should be injected subcutaneously into the abdomen, shoulder, thigh or buttocks, its temperature should be at room temperature.

The doctor determines the dose of insulin depending on the level of glucose in the patient's blood, the mode of administration is individual.

The correct technique for self-injection should be recommended by the attending physician.

The injection sites should be alternated; Humalog Mix 25 should not be injected into the same site more than once a month. Avoid getting insulin into the blood vessel. The injection site cannot be massaged after the procedure.

To properly insert the cartridge into the insulin delivery device and attach the needle, you should first study the manufacturer's instructions for this device and strictly follow it.

To resuspend insulin, the cartridge should be rolled between palms 10 times before direct use, then turned 10 times 180 ° and back until the contents look like milk. Stirring the solution relieves the glass ball inside the cartridge. Do not shake the cartridge vigorously so as not to cause the formation of foam, which makes it difficult to set the correct dose.

Do not use the suspension if flakes are found on visual inspection after mixing.

Introduction of Humalog Mix 25 is made in compliance with the rules of asepsis and antiseptics. After washing your hands and determining the injection site, it should be treated with an antiseptic. Then, after removing the outer protective cap from the needle and fixing the skin (by pinching a large fold or pulling it on), insert the subcutaneous needle and inject. After removing the needle, gently press the insertion site for a few seconds with a cotton swab without rubbing.

When using Humalog Mix 25 in a QuickPen syringe pen, the dose can be set with an accuracy of one unit. In the dose indicator window, even numbers are printed as numbers, odd numbers are printed as straight lines. If an error occurs while setting the dose, it can be corrected without losing insulin. The pen syringe is designed to inject from 1 to 60 IU (unit of action) of insulin per injection. It is recommended for use with pen needles from Becton, Dickinson and Company (BD). Before the procedure, you must make sure that the needle is firmly attached to the syringe pen.

Pulling the cap (without turning) of the syringe pen, remove it. Do not remove the label from the pen body. Make sure the insulin is correct for the type of insulin, check the expiration date and appearance. Then carefully roll the pen between your palms 10 times and turn it over 10 times. After wiping the rubber disc at the end of the cartridge holder with a swab soaked in alcohol, put a new needle in the cap straight axially onto the syringe pen, screwing it until it is fully attached. After removing the cap from the needle, check the flow of insulin from the syringe pen, do a single press on the cap until a stream appears from the needle. After making sure that the syringe pen is ready for the procedure, set the injection button to the number of units corresponding to the dose prescribed by the doctor. Fixing the skininsert the s / c needle and with your thumb firmly press the dose administration button in a straight axis until it stops and, holding it down, slowly count to five, this will provide a full dose of insulin. After removing the needle, gently press the injection site with a cotton swab for a few seconds. Put the protective cap on the needle. If insulin drips from the needle after the injection, this may indicate that the needle has not been held under the skin for a long time. The presence of one drop of insulin at the tip of the needle does not affect the dose.this may indicate that the needle is not kept under the skin for a long time. The presence of one drop of insulin at the tip of the needle does not affect the dose.this may indicate that the needle is not kept under the skin for a long time. The presence of one drop of insulin at the tip of the needle does not affect the dose.

After the procedure, you need to unscrew the needle with a protective cap and dispose of it, close the syringe pen with a cap.

In the case when the amount of insulin in the cartridge is less than the required dose, it can be used by making two injections. First, you need to enter the remainder from the previous cartridge, then - the missing amount from a new pen.

During the injection, you must not try to change the dose of insulin.

After opening, the syringe pen should be stored in a place protected from a source of heat and light at a temperature not exceeding 30 ° C, the drug is suitable for use within 28 days.

Side effects

• from the endocrine system: often - hypoglycemia (including loss of consciousness, death);
• from the immune system: possibly - local allergic reactions in the form of redness, itching or swelling at the injection site; rarely - allergic reactions of a systemic nature in the form of generalized itching, difficulty breathing, shortness of breath, decreased blood pressure, tachycardia, increased sweating (including life-threatening);
• local reactions: against the background of prolonged therapy, lipodystrophy may appear at the injection site.

Overdose

Symptoms: hypoglycemia, which may be accompanied by symptoms such as increased sweating, lethargy, headache, tachycardia, vomiting, confusion.

Treatment: oral glucose (sugar or foods containing sugar) is usually sufficient to relieve mild hypoglycemia. Adjustments to diet, insulin dose, or physical activity may be required. In moderately severe hypoglycemia, intramuscular (i / m) or s / c administration of glucagon and subsequent ingestion of carbohydrates are indicated.

To relieve severe conditions of hypoglycemia, accompanied by convulsions, neurological disorders or coma, use subcutaneous or im administration of glucagon or intravenous administration of a concentrated solution of dextrose (glucose). After the patient has regained consciousness, he should be offered a carbohydrate-rich food to avoid relapse. The patient needs close supervision.

special instructions

Local allergic reactions usually resolve on their own within a few days. They can be caused not only by insulin, but also by the used antiseptic or incorrect injection.

Changing the type of insulin or switching the patient to an insulin preparation from another manufacturer should be carried out under strict medical supervision. Newly prescribed insulin may have a different activity, type (for example, Hagedorn neutral protamine or Regular), species (human, animal, analog of human insulin) and / or method of production (DNA recombinant insulin or insulin of animal origin), therefore it is necessary to correct his dose.

It should be borne in mind that after switching from insulin of animal origin against the background of the introduction of human insulin, in some patients the symptoms-precursors of hypoglycemia may be less pronounced or differ from those that were observed in them against the background of the introduction of insulin of animal origin. The doctor should warn the patient about the possible change or complete disappearance of some of the precursor symptoms of hypoglycemia as a result of intensive insulin therapy, with diabetic neuropathy, long-term course of diabetes mellitus, treatment with beta-blockers.

The consequence of the use of inadequate doses or discontinuation of therapy, especially in insulin-dependent diabetes mellitus, can lead to hyperglycemia and diabetic ketoacidosis.

There may be a decrease in the need for insulin in patients with insufficient function of the thyroid gland, adrenal glands or pituitary gland, renal or hepatic insufficiency. Emotional stress, physical activity, changes in your usual diet, or certain medical conditions can increase your need for insulin.

When using Humalog Mix 25 in a syringe pen, it should be borne in mind that the device will not allow setting the dose if it exceeds the number of units remaining in it. If you are not sure of the full dose, you should not give another dose. The gray color of the dose administration button of the QuickPen syringe pen corresponds to the color of the strip on the label of the syringe pen and indicates the type of insulin, and the blue color of the body indicates the need to use it with the Humalog line. Do not store a pen with a needle attached to it! It is recommended to use a new needle for each injection, which must be disposed of after the procedure.

Influence on the ability to drive vehicles and complex mechanisms

During the period of application of Humalog Mix 25, care should be taken if it is necessary to perform potentially dangerous types of work, including driving.

In patients with frequent development of hypoglycemia, mild or absent symptoms of it-precursors, the advisability of driving a car should be assessed by a doctor and given recommendations individually.

Application during pregnancy and lactation

The undesirable effect of Humaloga Mix 25 on the course of pregnancy, the condition of the fetus or newborn has not been established when it is used during gestation.

Usually, in the first trimester of pregnancy, the need for insulin decreases, and in the second and third trimesters, it increases. Insulin therapy during pregnancy is essential to maintain adequate glucose control. During and immediately after childbirth, the need for insulin may decrease.

Women with diabetes should inform their doctor about planning a pregnancy or conception.

During lactation, to control glucose levels, it is possible to prescribe a diet or adjust the dose of insulin.

With impaired renal function

With renal failure, the need for insulin may decrease.

For violations of liver function

With liver failure, the need for insulin may decrease.

Drug interactions

With the simultaneous use of Humalog Mix 25:

• glucocorticosteroids, phenothiazine derivatives, oral contraceptives, thyroid hormonal agents, beta ₂ -adrenomimetics (including ritodrin, terbutaline, salbutamol), danazol, thiazide diuretics, chlorprothixene, lithium preparations, isoniazid, diazoglycemic acid: promote nicotinic acid;
• oral hypoglycemic drugs, beta-blockers, anabolic steroids, guanethidine, tetracyclines, salicylates, fenfluramine, sulfonamides, monoamine oxidase inhibitors, octreotide, angiotensin-converting enzyme inhibitors (enalapril, antagonists of ethaginol-containing drugs);
• clonidine, beta-blockers, reserpine: can mask the symptoms of hypoglycemia.

Analogs

Analogs of Humalog Mix 25 are: Humalog Mix 50, Apidra, Actrapid, Humulin Regular, Intral SPP, Intral HM, Farmasulin, Iletin II Regular.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures between 2 and 8 ° C, keep away from freezing and exposure to direct sunlight or heating devices.

Shelf life is 2 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews of Humalog Mix 25

Reviews of Humalog Mix 25 are positive. The simplicity of the pen device allows patients to inject themselves, and most importantly, in the correct dose. Indicate the effectiveness of the drug, a noticeable improvement in glycemic control, rapid action. For many, the disadvantage of an effective hypoglycemic drug is its price.

Price for Humalog Mix 25 in pharmacies

The price of Humalog Mix 25 for a package containing 5 cartridges of 3 ml can range from 1889 rubles.

Humalog Mix 25: prices in online pharmacies

Drug name Price Pharmacy

Humalog Mix 25 100 IU / ml suspension for subcutaneous administration 3 ml 5 pcs. 1609 RUB Buy

Humalog Mix 25 100 IU / ml suspension for subcutaneous administration 3 ml 5 pcs. 1671 RUB Buy

Humalog Mix 25 suspension for n / a input. 100 units / ml 3ml 5 pcs. 1856 RUB Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!